Immunoreactivity of a new CD5 antibody with normal epithelium and malignant tumors including thymic carcinoma

American Journal of Clinical Pathology

Volumn 111, Issue 2, 1999, Pages 235-240

  Tateyama, Hisashi ^a   Eimoto, Tadaaki ^a   Tada, Toyohiro ^a   Hattori, Hideo ^a   Murase, Takayuki ^a   Takino, Hisashi ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

CD5; Immunohistochemistry; Malignant mesothelioma; Mediastinum; Thymic carcinoma; Thymoma

Indexed keywords

CD5 ANTIGEN;

ANTIGEN RETRIEVAL; ARTICLE; CANCER DIAGNOSIS; CELL MEMBRANE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTE SUBPOPULATION; MALIGNANT TRANSFORMATION; MEDIASTINUM TUMOR; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYMOMA; THYMUS CANCER;

EID: 0032937131     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.2.235     Document Type: Article

References (29)

1. Arber DA, Weiss LM. CD5: a review. Appl Immunohistochemistry. 1995;3:1-22.
2. Chan JKC, Banks PM, Cleary ML, et al. A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group). Histopathology. 1994;25:517-536.
3. + cells in paraffin sections. Am J Clin Pathol. 1996;106:370-373.
4. Kaufmann O, Flath B, Spath-Schwalbe E, et al. Immunohistochemical detection of CD5 with monoclonal antibody 4C7 on paraffin sections. Am J Clin Pathol. 1997;108:669-673.
5. Hishima T, Fukayama M, Fujisawa M, et al. CD5 expression in thymic carcinoma. Am J Pathol. 1994;145:268-275.
6. Dorfman DM, Shahsafaei A, Chan JKC. Thymic carcinomas, but not thymomas and carcinomas of other sites, show CD5 immunoreactivity. Am J Surg Pathol. 1997;21:936-940.
7. Berezowski K, Grimes MM, Gal A, et al. CD5 immunoreactivity of epithelial cells in thymic carcinoma and CASTLE using paraffin-embedded tissue. Am J Clin Pathol. 1996;106:483-486.
8. Dorfman DM, Shahsafaei A. Usefulness of a new CD5 antibody for the diagnosis of T-cell and B-cell lymphoproliferative disorders in paraffin sections. Mod Pathol. 1997;10:859-863.
9. Kirchner T, Schalke B, Buchwald J, et al. Well-differentiated thymic carcinoma: an organotypical low-grade carcinoma with relationship to cortical thymoma. Am J Surg Pathol. 1992;16:1153-1169.
10. Garcia RL, Coltrera MD, Gown AM. Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissue: comparison with flow cytometric analysis. Am J Pathol. 1989;134:733-739.
11. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994;173:371-379.
12. Shimosato Y, Mukai K. Tumors of the mediastinum. In: Rosai J, ed. Atlas of Tumor Pathology. 3rd series, Fascicle 21. Washington, DC: Armed Forces Institute of Pathology; 1997:40-158.
13. Rosai J. Ackerman's Surgical Pathology. 8th ed. St Louis, Mo: Mosby; 1996:442-457.
14. Shimosato Y. Controversies surrounding the subclassification of thymoma. Cancer. 1994;74:542-544.
15. Morinaga S, Sato Y, Shimosato Y, et al. Multiple thymic squamous cell carcinoma associated with mixed type thymoma. Am J Surg Pathol. 1987;11:982-988.
16. Suster S, Moran CA. Primary thymic epithelial neoplasms showing combined features of thymoma and thymic carcinoma: a clinicopathologic study of 22 cases. Am J Surg Pathol. 1996;20:1469-1480.
17. Brocheriou I, Carnot F, Briere J. Immunohistochemical detection of bcl-2 protein in thymoma. Histopathology. 1995;27:251-255.
18. Chen F-F, Yan J-J, Jin Y-T, et al. Detection of bcl-2 and p55 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol. 1996;27:1089-1092.
19. Chen F-F, Yan J-J, Chang K-C, et al. Immunohistochemical localization of mcl-1 and bcl-2 proteins in thymic epithelial tumours. Histopathology. 1996;29:541-547.
20. Tateyama H, Eimoto T, Tada T, et al. Apoptosis, bcl-2 protein, and Fas antigen in thymic epithelial tumors. Mod Pathol. 1997;10:983-991.
21. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol. 1996;20:1037-1046.
22. Kennedy AD, King G, Kerr KM. HBME-1 and antithrombomodulin in the differential diagnosis of malignant mesothelioma of pleura. J Clin Pathol. 1997;50:859-862.
23. Donna A, Betta P-G, Chiodera P, et al. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies. Hum Pathol. 1997;28:929-937.
24. Ordóñez: NG. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol. 1997;21:1599-1408.
25. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. Am J Surg Pathol. 1997;21:1409-1419.
26. Ordóñez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the M. D. Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-89.
27. Wick MR. Immunophenotyping of malignant mesothelioma [editorial]. Am J Surg Pathol. 1997;21:1395-1398.
28. Shimosato Y, Kameya T, Nagai K, et al. Squamous cell carcinoma of the thymus: an analysis of eight cases. Am J Surg Pathol. 1977;1:109-121.
29. Suster S, Rosai J. Thymic carcinoma: a clinicopathologic study of 60 cases. Cancer. 1991;67:1025-1032.